Harrow HROW
NASDAQ HROW
$40.95 -1.11 (-2.64%)
At close: Aug 21, 2026 · 4:00 PM EDT

Harrow (HROW) Cash from Investing Activities (2012 - 2026)

Harrow (HROW) posted quarterly Cash from Investing Activities of -$18.2 million for Q1 2026, down 8486.32% year-over-year from $217055.9 in Q1 2025, and down 284.84% quarter-over-quarter from -$4.7 million in Q4 2025.

Harrow (HROW) Cash from Investing Activities (2012 - 2026) Analysis & Trends

Harrow's Cash from Investing Activities history runs 15 years deep, the most recent figure standing at -$18.2 million for Q1 2026.

  • In Q1 2026, Cash from Investing Activities fell 8486.32% year-over-year to -$18.2 million; the TTM figure through Mar 2026 stood at -$23.5 million (up 29.5% YoY), while the FY2025 annual figure was -$5.5 million, up 83.54% from the prior year.
  • Cash from Investing Activities for Q1 2026 stood at -$18.2 million, down from -$4.7 million in the prior quarter.
  • The five-year high for Cash from Investing Activities was $5.1 million in Q2 2024, with the low at -$131.0 million in Q1 2023.
  • The 5-year median for Cash from Investing Activities is -$410000.0 (2022), against an average of -$12.4 million.
  • The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities plunged 31843.9% in 2023, then soared 508.57% in 2024.
  • Harrow's Cash from Investing Activities stood at -$5000.0 in 2022, then plunged by 3960.0% to -$203000.0 in 2023, then tumbled by 18402.46% to -$37.6 million in 2024, then soared by 87.41% to -$4.7 million in 2025, then slumped by 284.84% to -$18.2 million in 2026.
  • Business Quant data shows HROW's Cash from Investing Activities at -$18.2 million in Q1 2026, -$4.7 million in Q4 2025, and -$225000.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Haleon 44.51 Bn 43.55 Bn - -
2 Teva Pharmaceutical Industries 43.52 Bn 39.86 Bn 2.15 Bn -491.00 Mn
3 Zoetis 32.43 Bn 30.75 Bn 1.05 Bn -300.00 Mn
4 Takeda Pharmaceutical 28.63 Bn 22.83 Bn 5.10 Bn -550.24 Mn
5 United Therapeutics 21.87 Bn 19.21 Bn 683.80 Mn 87.50 Mn
6 Viatris 18.98 Bn 18.09 Bn 1.46 Bn -51.60 Mn
7 Neurocrine Biosciences 15.43 Bn 15.04 Bn 935.80 Mn -135.40 Mn
8 Elanco Animal Health 12.02 Bn 11.49 Bn 798.00 Mn -110.00 Mn
9 Dr Reddys Laboratories 10.14 Bn 9.98 Bn - -
10 Harrow 1.53 Bn 1.45 Bn 50.36 Mn -534,000.00

Historic Data

Download Data
DateValue
Jun 30, 2026 -534,000.00
Jun 30, 2026 -534,000.00
Mar 31, 2026 -18.20 Mn
Mar 31, 2026 -18.20 Mn
Dec 31, 2025 -4.73 Mn
Dec 31, 2025 -4.73 Mn
Sep 30, 2025 -225,000.00
Sep 30, 2025 -225,000.00
Jun 30, 2025 -293,000.00
Jun 30, 2025 -293,000.00
Mar 31, 2025 -212,000.00
Mar 31, 2025 -212,000.00
Dec 31, 2024 -37.56 Mn
Dec 31, 2024 -37.56 Mn
Sep 30, 2024 -597,000.00
Sep 30, 2024 -597,000.00
Jun 30, 2024 5.10 Mn
Jun 30, 2024 5.10 Mn
Mar 31, 2024 -110,000.00
Mar 31, 2024 -110,000.00